BioMarin Pharmaceutical Value Stock - Dividend - Research Selection
BioMarin Pharmaceutical
ISIN: US09061G1013, WKN: 924801
Market price: 83,70 USD
BioMarin Pharmaceutical Fundamental data and company key figures of the share
| Annual reports in USD | |||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Key figures | 01-03-2021 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Cash flow | |||||||||||||||||||||||||||||||||||||||||||||||||
| Net operating cash flow | 85.365.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Capital Expenditures | -114.312.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Free cash flow | -28.947.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Balance sheet | |||||||||||||||||||||||||||||||||||||||||||||||||
| Total Equity | 4.106.000.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Liabilities & Shareholders equity | 5.848.020.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Income statement | |||||||||||||||||||||||||||||||||||||||||||||||||
| Net income | 859.100.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Eps (diluted) | 4,530 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Diluted shares outstanding | 181.000.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Net sales/revenue | 1.805.860.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!
How our site works ...
✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe
Price for monthly subscription $ 19.99 / month including VAT.
| Description | Data |
|---|---|
| Symbol | BMRN |
| Market Capitalization | 15.149.700.096,00 USD |
| Country | United States |
| Indices | NASDAQ 100,NASDAQ Comp.,MSCI World Index |
| Sectors | Biotechnology |
| Raw Data Source | US GAAP in Millionen USD |
| Stock Split | |
| Internet | www.biomarin.com |
Description of the company
BioMarin Pharmaceutical Inc. (BioMarin) develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Company's product portfolio is comprised of four approved products and multiple investigational product candidates. Approved products include Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). It is conducting clinical trials on several product candidates for the treatment of various diseases. They include Vimizim (formerly referred to as GALNS), an enzyme replacement therapy for the treatment of Mucopolysaccharidosis Type IV or Morquio Syndrome Type A (MPS IV A), PEG-PAL, an enzyme substitution therapy for the treatment of phenylketonuria (PKU), and BMN-701, an enzyme replacement therapy for Pompe disease, a glycogen storage disorder. On January 7, 2013, the Company acquired Zacharon Pharmaceuticals.